Elinzanetant

Chemical formula: C₃₃H₃₅F₇N₄O₃  Molecular mass: 668.26 g/mol  PubChem compound: 16063568

Therapeutic indications

Elinzanetant is indicated for:

Moderate to severe vasomotor symptoms (VMS)

Population group: women, only adults (18 years old or older)

Elinzanetant is indicated for the treatment of moderate to severe vasomotor symptoms (VMS):

  • associated with menopause
  • caused by adjuvant endocrine therapy (AET) related to breast cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Elinzanetant is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2025: LYNKUET Soft capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈